Arene ruthenium (ii) compounds and their use in cancer therapy

Details Arene ruthenium (ii) compounds and their use in cancer therapy Arene ruthenium (ii) compounds and their use in cancer therapy

A - Human Necessities

61

K

A61K 31/28 (2006.01) A61P 35/00 (2006.01) C07F 15/00 (2006.01)

Patent

CA 2578280

A ruthenium (II) compound of formula (I): or a solvate or prodrug thereof, wherein: R1, R1, R3, R4, R5 and R6 are independently selected from H, C1-7 alkyl, C5-20 aryl, C3-20 heterocyclyl, halo, ester, amido, acyl, sulfo, sulfonamido, ether, thioether, azo, amino, or R1 and R2 together with the ring to which they are attached form a saturated or unsaturated carbocyclic or heterocyclic group containing up to three 3- to 8- membered carbocyclic or heterocyclic rings, wherein each carbocyclic or heterocyclic ring may be fused to one or more other carbocyclic or heterocyclic rings; X is a neutral or negatively charged N- or S- donor ligand; Y is a counterion; m is 0 or 1; q is 1, 2 or 3; C' is C1-12 alkylene bound to two A groups; p is 0 or 1 and r is 1 when p is 0 and r is 2 when p is 1; and A and B are each independently O- donor, N-donor or S-donor ligands, and may be connected to one another. The compounds are used in cancer therapy.

L'invention concerne un composé ruthénium (II) de formule (I): (I) ou un solvate ou un promédicament de celui-ci. Dans la formule, R1, R1, R3, R4, R5 et R6 sont indépendamment sélectionnés parmi H, alkyle C1-7, aryle C5-20, hétérocyclyl C3-20, halo, ester, amido, acyle, sulfo, sulfonamido, éther, thioéther, azo, amino, ou bien R1 et R2 forment ensemble avec le noyau auquel ils sont attachés un groupe carbocyclique ou hétérocyclique saturé ou insaturé contenant jusqu'à trois noyaux carbocycliques ou hétérocycliques à 3- à 8- membres, chaque noyau carbocyclique ou hétérocyclique pouvant être réuni par fusion à un ou plusieurs autres noyaux carbocycliques ou hétérocycliques; X est un ligand donneur N- ou S- neutre ou à charge négative; Y est un contre-ion; m désigne 0 ou 1; q signifie 1, 2 ou 3; C' représente alkylène C1-12 lié à deux groupes A; p désigne 0 ou 1; r signifie 1 lorsque p représente 0 et r signifie 2 lorsque p représente 1; A et B sont chacun indépendamment des ligands donneurs O-, N- ou S-, et ils peuvent être mutuellement reliés. Ces composés servent dans la thérapie du cancer.

Affiliated with

Also associated with

Rating

Arene ruthenium (ii) compounds and their use in cancer therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Arene ruthenium (ii) compounds and their use in cancer therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arene ruthenium (ii) compounds and their use in cancer therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2005325